Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
imo...axel took the blue pill and it was't pretty....MRNA
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
Did you take the blue pill?
this company isn't likely to depend on the vaccine for very long. Moderna has several candidates across treatment areas in late-stage development. And the company recently said it aims to launch as many as 15 products over the coming five years.
If Moderna succeeds, this could be big, catapulting the company to annual revenue of as much as $30 billion a few years after launch. These potential products span the areas of oncology, rare diseases, and, of course, respiratory diseases such as the coronavirus. The closest to market include a vaccine candidate for respiratory syncytial virus and a combination shot to prevent coronavirus and flu. They could launch in 2024 and 2025
imo...oh and dont't forget JNJ......I own that POS also~
fwm
IHuser
imo... let's see axel I own MRNA, PFE, ZTS, GD, LMT, DIS, whos next who wants a piece of my mind.....come for it~
ready~
IHuser
imo... patriots should catch Trump blunder Sessions COI debuckle...
elementary school~ time wasted
MRNA
IHuser
imo...everything can happen axel....our Trump jokes about landing in USA and looks like a third world country.....MRNA....that's the people's third world country he is making fun of....
IHuser
everything can happen-The company is scheduled to release its earnings on November 2, 2023. The company is predicted to post an EPS of -$1.80, indicating a 171.15% decline compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $1.36 billion, indicating a 59.47% decrease compared to the same quarter of the previous year.
imo... It is early to say, only time will tell- money machine-
:-Moderna's valuation can be difficult to gauge. You can't truly rely on earnings on revenue multiples, as the business is going to look a lot different as it transitions to other products.
It is early to say, only time will tell- money machine-
:-Moderna's valuation can be difficult to gauge. You can't truly rely on earnings on revenue multiples, as the business is going to look a lot different as it transitions to other products. It's currently trading at only 3 times its trailing revenue. But if the company's sales fall further, then that sales multiple will quickly rise. Plus, declining revenue will put pressure on its bottom line.
mRNA-1647: a vaccine for cytomegalovirus, which could generate peak sales between $2 billion and $5 billion.
mRNA-1345: a vaccine for respiratory syncytial virus, which may bring in over $2 billion in peak annual sales.
mRNA-1893: a vaccine for Zika virus that could be worth hundreds of millions of dollars.
A bit of a longer shot is the company's cancer vaccine, mRNA-4157, that it is working on with Merck
the work continues_ Moderna, meanwhile, is working with Big Pharma Merck & Co., known as MSD here in Spain, on a personalized cancer vaccine called mRNA-4157 that is soon to enter phase 3. While the companies didn’t have major news to reveal at ESMO, both had a presence.
ESMO: Moderna, BioNTech's post-COVID futures in oncology hit manufacturing realities
https://www.fiercepharma.com/manufacturing/moderna-biontechs-post-covid-futures-oncology-hit-manufacturing-realities
Let us move forward towards a new future$
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
https://finance.yahoo.com/news/caris-life-sciences-moderna-announce-103000173.html
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-First-Participant-Dosed-in-Phase-3-Study-of-mRNA-1083-a-Combination-Vaccine-Against-Influenza-and-COVID-19/default.aspx
imo... axel I still am a god send and my tribe is pulverizing this POS in front of your eyes and they will not stop and it is not about the money.....$
IHuser
OBVIOUSLY, I wasn’t referring strictly to the attributes of color blindness
YOu obviously don't understand colorblindness.
There are variations but let say red/green you just confuse the various shades of these two colors.
But colorblind people do SEE Light, and many colors within. LOL
Now seeing the difference between facts and speculation, that's another ball of wax! Hah!
is a fight against ignorance...let's see what happens
he was a godsend less than $80>>>>>>>>>>
imo... hey Vex.......what goes in your arm and is RED across the boards,,,? you can buy some vowels if needed.... CONsanants are free~
M R N ?
IHuser
" updates coming soon" On October 23rd, Dr. Jeffrey S. Weber we will be presenting clinical results and treatment outcomes from our Phase 2b KEYNOTE-942/mRNA-4157-P201 trial. cancer
IH- you only live once.....relax baby
And it appears the colorblind can see no light
Facts have no color
Take it from there
imo...axel.......without a god conscience and brotherhood in humanity you have nothing but our wrath on ihub....MRNA
IHuser
I THINK WHITE YOU THINK BLACK ....freedom of thought
the world moves forward anyway..no problem$$$$$$
time will tell-Breast cancer vaccine trial gives new hope to patients https://www.fox29.com/video/1294611
Where does the division lie and why
Other than false science
To cover up
IH- time will tell. Ohio-native Jennifer Davis received her last dose in 2021 and is still cancer-free
Now, the researchers have set their sights on recruiting women who have never had triple-negative cancer but are at higher risk in a bid to see if the vaccine could prevent the cancer from attacking in the first place.
imo... axel this woman was apparently dietarily deficient.....cancer will not even set in if the body has an alkaline ph level....time to waky waky folks.....MRNA
IHuser
questions to shift to a new future....
‘I Was The First Person To Get The New Breast Cancer Vaccine—And It Completely Changed My Life’https://t.co/KOTsaZn7s7 pic.twitter.com/af4qCcCVvD
— Anixa Biosciences (@AnixaBio) October 9, 2023
IH_ the twisted mind of antivaxxer has no limits. you will have the opportunity to grow!
you're always a brother anti MRNA antivaxxer
It doesn't really bother me$$$$$$$$$
IH-fortunately I’m not addicted to anyone, Open your eyes and stop dreaming.
Open your ears and listen...I'm a stockholder,They are not paid by MRNA
imo...axel ....it's ok to read the walls, but remember employees must wash hands before returning to work....MRNA...
it keep the corona viruses in check~
IHuser
The projected fair value for Moderna is US$124 based on 2 Stage Free Cash Flow to Equity
Moderna's US$86 share price signals that it might be 30% undervalued "minimum"
Then you have to add the filling..
Over the next five years, the Company expects to launch up to 15 new products addressing high unmet needs, to bring up to 50 new candidates into clinical trials and to continue expanding the field of mRNA into new applications
It's written on the wall over here.
iH- shareholder of MRNA ...You're really becoming one of us, kid.
IH- ANTIVAXXER harmless......we are waiting ,your triple hole do not be afraid!!!!!!
The music gave the pioneers strength and courage.
LOL dilution--- repurchased 4.4 million shares in Q2 for a total of $628 million....
The $3 billion share repurchase program announced in February 2022 was completed early in the fourth quarter 2022
good try$$$$$$$
imo... we can see insiders fleeing....overpriced tenders coming whats next boys...dilution......run fast people run go now....imo MRNA
Well, you might consider all those billions in cash first.
imo... axel what is the approximate auction value of the desks and chairs and phones and the break room mini-fridge...?? I'm thinking about a long position.
IHuser
NO. Moderna does not endorse TRC Capital's unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to TRC Capital's offer because the offer is at a price below the current market value of Moderna common stock and is subject to numerous conditions. Per the terms of the offer, any shareholders who tender (or have already tendered) their shares can withdraw them prior to the expiration of the offer, currently scheduled for 12:01 a.m., New York City time, on October 13, 2023, in accordance with the offering documents, but subject to extension at TRC Capital's discretion.
that news is 2 weeks old. Pfizer news also isn't helping.
Bummer, new 52 week low. EU delayed approval of Novavax as well. Funny, I read a Barron's article this weekend saying Moderna was a strong buy.
Barron's has become a junk financial rag too. I'm worried the WSJ is the last man standing and they are starting to drift into the false narratives.
$91 dollars. Losing lots of air. market appears to be saying they are a one trip pony?
imo... axel anybody coming at me with a needle is in range..... --------------------------------------------> MRNA
IHuser
IHuser - you are a, triple vaccinated RNA
Followers
|
175
|
Posters
|
|
Posts (Today)
|
1
|
Posts (Total)
|
13524
|
Created
|
12/10/18
|
Type
|
Free
|
Moderators DewDiligence Vexari axelvento |
2021 was a year of monumental impact and change for Moderna
Moderna entered 2021 with a strong cash position of approximately $5.25 billion. We have used this capital to invest in R&D and scale our development pipeline and manufacturing capabilities to maximize our impact on human health.
As we close our books for 2021, the company’s cash, cash equivalents and investments as of December 31, 2021, were more than $17 billion. We now have the resources to scale our investments and do even more to positively impact human health with mRNA medicines. This is just the beginning.
.
https://www.modernatx.com/newsroom/our-blog-coding-region/moderna-2021-shareholder-letter
Moderna is entering 2022 with a remarkable team poised to continue advancing mRNA vaccines and therapeutics into new areas for patients. We have a clear and exciting strategic path to do so, and a strong cash position.
Priority two is to go after the most important latent viruses and develop first-in-class vaccines against them. We want to protect our fellow human beings from suffering from the long-term damage caused by these viruses. Too many people have the quality of their health impacted because decades before, they were infected with a latent virus. We envision a world where vaccines against all the most important latent viruses are available to all.
Priority three is to bring to market therapeutics based on mRNA-encoded proteins, like our current pipeline in oncology, cardiology, rare genetic diseases and autoimmune diseases.
Priority four is to bring to market innovative therapeutics based on mRNA-encoded gene editing enzymes.
Moderna expects to enroll approximately 34,000 participants in multiple countries
RSV is a leading cause of severe respiratory illness in older adults (65+) and young children; there is no approved vaccine to prevent RSV
RSV illness in older adults results in an estimated $3 billion in annual medical costs in the U.S. each year
NOVEMBER, 18, 2021
https://investors.modernatx.com/news/news-details/2021/Moderna-Announces-First-Participant-Dosed-in-Phase-2-3-Study-of-its-mRNA-Respiratory-Syncytial-Virus-RSV-Vaccine/default.aspx
MODERNA ANNOUNCES POSITIVE DATA FROM PHASE 2 STUDY OF MRNA VEGF-A THERAPEUTIC IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose
SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Q4 2021 revenues of $7.2 billion; GAAP net-income of $4.9 billion and GAAP diluted EPS of $11.29
Full year 2021 revenues of $18.5 billion; GAAP net-income of $12.2 billion and GAAP diluted EPS of $28.29
Moderna increased its 2022 signed advance purchase agreements to approximately $19 billion, with additional signed options of approximately $3 billion; numerous discussions ongoing with governments for the fall of 2022 and 2023
Moderna received full U.S. FDA approval for COVID-19 vaccine, Spikevax
Moderna announces new bivalent booster candidate (mRNA-1273.214) combining Omicron-specific booster candidate (mRNA-1273.529) and the Moderna COVID-19 vaccine (mRNA-1273)
Company now has 44 programs in development
Moderna announces a new $3 billion share repurchase plan
https://investors.modernatx.com/news/news-details/2022/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates/default.aspx
Facility to manufacture drug substance with opportunity for fill/finish and packaging capabilities
Moderna investing up to $500 million to produce up to 500 million doses each year for the African continent
Moderna will invest in building mRNA capabilities in Africa
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Memorandum-of-Understanding-with-the-Government-of-the-Republic-of-Kenya-to-Establish-its-First-mRNA-Manufacturing-Facility-in-Africa/default.aspx
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |